Rohila et al. investigated the therapeutic targeting of Syk with fostamatinib alone and in combination with anti-PDL1 mAb in NB using syngeneic cell lines with MYCN amplification and myeloid Syk KO mice. The gene discussed is MYCN; the disease is neuroblastoma.